Manali I. Patel

Dr. Manali I. Patel

Department of Medical Oncology, Stanford University, 3150 Porter Drive, Palo Alto, CA 94306 USA
orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 August 2020 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
MPManali I. Patel
Manali I. Patel
ALAna Maria Lopez
Ana Maria Lopez
WBWilliam Blackstock
William Blackstock
KRKatherine Reeder-Hayes
Katherine Reeder-Hayes
EME. Allyn Moushey
E. Allyn Moushey
WTWilliam Tap
William Tap
ASCO strives, through research, education, and promotion of the highest quality of patient care, to create a world where cancer is prevented and every survivor is healthy. In this pursuit, cancer health equity remains the guiding institutional principle that applies to all its activities across the cancer care continuum. In 2009, ASCO committed to addressing differences in cancer outcomes in its original policy statement on cancer disparities. Over the past decade, despite novel diagnostics and therapeutics, together with changes in the cancer care delivery system such as passage of the Affordable Care Act, cancer disparities persist. Our understanding of the populations experiencing disparate outcomes has likewise expanded to include the intersections of race/ethnicity, geography, sexual orientation and gender identity, sociodemographic factors, and others. This updated statement is intended to guide ASCO’s future activities and strategies to achieve its mission of conquering cancer for all populations. ASCO acknowledges that much work remains to be done, by all cancer stakeholders at the systems level, to overcome historical momentum and existing social structures responsible for disparate cancer outcomes. This updated statement affirms ASCO’s commitment to moving beyond descriptions of differences in cancer outcomes toward achievement of cancer health equity, with a focus on improving equitable access to care, improving clinical research, addressing structural barriers, and increasing awareness that results in measurable and timely action toward achieving cancer health equity for all.

1 July 2022 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
RORandall Oyer
Randall Oyer
PHPatricia Hurley
Patricia Hurley
LBLeigh Boehmer
Leigh Boehmer
SBSuanna Steeby Bruinooge
Suanna Steeby Bruinooge
KLKathryn Levit
Kathryn Levit
LPLori J. Pierce
Lori J. Pierce
A concerted commitment across research stakeholders is necessary to increase equity, diversity, and inclusion (EDI) and address barriers to cancer clinical trial recruitment and participation. Racial and ethnic diversity among trial participants is key to understanding intrinsic and extrinsic factors that may affect patient response to cancer treatments. This ASCO and Association of Community Cancer Centers (ACCC) Research Statement presents specific recommendations and strategies for the research community to improve EDI in cancer clinical trials. There are six overarching recommendations: (1) clinical trials are an integral component of high-quality cancer care, and every person with cancer should have the opportunity to participate; (2) trial sponsors and investigators should design and implement trials with a focus on reducing barriers and enhancing EDI, and work with sites to conduct trials in ways that increase participation of under-represented populations; (3) trial sponsors, researchers, and sites should form long-standing partnerships with patients, patient advocacy groups, and community leaders and groups; (4) anyone designing or conducting trials should complete recurring education, training, and evaluation to demonstrate and maintain cross-cultural competencies, mitigation of bias, effective communication, and a commitment to achieving EDI; (5) research stakeholders should invest in programs and policies that increase EDI in trials and in the research workforce; and (6) research stakeholders should collect and publish aggregate data on racial and ethnic diversity of trial participants when reporting results of trials, programs, and interventions to increase EDI. The recommendations are intended to serve as a guide for the research community to improve participation rates among people from racial and ethnic minority populations historically under-represented in cancer clinical trials. ASCO and ACCC will work at all levels to advance the recommendations in this publication.

1 February 2015 in Cancer Epidemiology, Biomarkers & Prevention
Verified
Journal Article
Open access
PDF file
MPManali I. Patel
Manali I. Patel
YMYifei Ma
Yifei Ma
BMBeverly Mitchell
Beverly Mitchell
KRKim F. Rhoads
Kim F. Rhoads
Background: We previously demonstrated disparate acute myelogenous leukemia (AML) survival for black and Hispanic patients; these differences persisted despite younger ages and higher prevalence of favorable cytogenetics in these groups. This study determined: (i) whether there are differences in treatment delivered to minorities, and (ii) how these differences affect outcomes in AML. We hypothesize that differences in treatment explain some proportion of survival disparities.

1 October 2013 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
MPManali I. Patel
Manali I. Patel
CSClayton W. Schupp
Clayton W. Schupp
SGScarlett L. Gomez
Scarlett L. Gomez
ECEllen T. Chang
Ellen T. Chang
HWHeather A. Wakelee
Heather A. Wakelee
Purpose: Hispanics in the United States have lower age-adjusted mortality resulting from non–small-cell lung cancer (NSCLC) compared with non-Hispanic whites (NHWs). The purpose of this study was to evaluate individual, clinical, and neighborhood factors in survival among Hispanics with NSCLC.Patients and Methods: We performed a retrospective analysis of NHWs and Hispanics with NSCLC between 1998 and 2007 in the California Cancer Registry (follow-up to December 2009). Kaplan-Meier curves depict survival by nativity for Hispanics with NSCLC. Cox proportional hazards models estimated hazard of mortality by race with adjustment for individual (age, sex, marital status), clinical (histologic grade, surgery, irradiation, chemotherapy), and neighborhood factors (neighborhood socioeconomic status, ethnic enclave).Results: We included 14,280 Hispanic patients with NSCLC. Foreign-born Hispanics had 15% decreased risk of disease-specific mortality resulting from NSCLC compared with NHWs (hazard ratio [HR], 0.85; 95% CI, 0.83 to 0.88) after adjustment for individual, clinical, and neighborhood factors. After adjustment for individual factors, compared with US-born Hispanics, foreign-born Hispanics had 10% decreased risk of disease-specific mortality (HR, 0.90; 95% CI, 0.87 to 0.96). Clinical and neighborhood factors slightly moderated the survival benefit for foreign-born patients. A modestly more pronounced survival advantage was seen for foreign-born Hispanics living in low socioeconomic and high Hispanic enclave neighborhoods as compared with US-born Hispanics (HR, 0.86; 95% CI, 0.81 to 0.90).Conclusion: Foreign-born Hispanics with NSCLC have a decreased risk of disease-specific mortality compared with NHWs and US-born Hispanics with NSCLC. Neighborhood factors slightly moderate this survival advantage. This survival advantage is slightly more pronounced in lower socioeconomic and higher Hispanic enclave neighborhoods.

1 July 2021 in JCO Oncology Practice
Verified
Journal Article
Closed access
FHFay J Hlubocky
Fay J Hlubocky
BSBanu E. Symington
Banu E. Symington
DMDaniel C. McFarland
Daniel C. McFarland
CGColleen M Gallagher
Colleen M Gallagher
KDKonstantin H. Dragnev
Konstantin H. Dragnev
TSTait D. Shanafelt
Tait D. Shanafelt

30 June 2022 in JAMA Oncology
Verified
Journal Article
Open access
PDF file
MPManali I. Patel
Manali I. Patel
KKKristopher Kapphahn
Kristopher Kapphahn
MDMarilyn Dewland
Marilyn Dewland
VAVeronica Aguilar
Veronica Aguilar
BSBlanca Sanchez
Blanca Sanchez
DPDavid J. Park
David J. Park
National guidelines recommend advance care planning (ACP) and symptom management for patients with advanced stages of cancer,1-3 yet a minority receive such care.4-6 This deficiency leads to lack of prognostic awareness7-9 and undertreated symptoms, which result in avoidable acute care use,10 care that differs from patients’ preferences,11-14 and psychological and physical distress.15,16 Although ACP and proactive symptom management can reduce acute care use and improve patient experiences,15,17-19 multilevel barriers inhibit delivery of such care. These include limited clinician time, lack of reimbursement, and cancer and palliative care workforce shortages.20-24